spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Clinical Services Welcomes Marc Rees to its International Clinical Sales Team

PCI Pharma Services

Philadelphia, USA – August 10, 2017

 

 Leading outsourcing services provider PCI Clinical Services has announced the appointment of Marc Rees in the role of Business Development Manager responsible for UK and Ireland.

Marc brings an extensive background in clinical and pharmaceutical development services, having worked for more than 20 years in relevant business development roles for leading contract development organizations and pharmaceutical services providers. Marc has experience working within the technical roles in pharmaceuticals as well as business development, demonstrating an excellent well-rounded knowledge of the sector.

Marc will be responsible for account management and territory growth in the UK and Ireland for the company’s international clinical packaging and logistics services, maintaining and growing market share with key customers while developing new business, as well as identifying opportunities for PCI’s high potency oral solid manufacturing, commercial packaging and analytical testing services.

Paul Viggers, Clinical Business Development Director, stated: “We are excited for the breadth of experience Marc is adding to our current team. He brings with him a proven track record in supporting clients across the clinical and pharmaceutical sector. His background will be invaluable in helping our clients realize successful clinical trials and shepherding to commercialization.”

Marc stated: “It is great to be working alongside the amazing team at PCI. I have always worked in the sector so I have great background to leverage for the benefit of our clients. I am looking forward to getting into my new role and utilizing my experiences and insights to deliver the industry’s leading experience to both new and current clients.”

PCI has announced considerable investment in its clinical trials business over the past year, including the expansion of its Cold Chain infrastructure at its North American clinical logistics facility in Rockford, IL. The additional expansion of on-site cryogenic storage complements its extensive refrigerated and frozen on-site storage. In addition, the company announced a significant site expansion of its Bridgend, Wales, UK clinical centre of excellence. PCI’s Bridgend site specialises in a broad range of temperature controlled packaging, storage and distribution capabilities.

These developments follow PCI’s announcement of its site expansion for its drug development and clinical trial manufacturing center of excellence in Tredegar, Wales, UK, including the purchase of a fully contained Xcelodose 600 unit for contained development of potent compounds in early phase clinical study.

To find out more about PCI, please visit www.pciservices.com.

About PCI


The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit
www.pciservices.comor follow us on Twitter at @PCI_Social.

Contact

Chantel Richman / Fotini Efstathiou at Remarkable Content
chantel.richman@remarkablegroup.co.uk / Fotini@remarkablegroup.co.uk

T: 0117 247 0158 / 01962 853 929
phone +44 (0)1495 713 633
email sales@pciservices.com
web www.pciservices.com
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

Edinburgh, UK – September 20th, 2017 - Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).
More info >>


White Papers

Autoinjectors From Planning to Launch

SHL Group

Looking at the rising trend towards self-administration therapies, injectable drug delivery devices such as pen injectors, autoinjectors and needle free injectors show a significant growth potential in the near future. In 2010, the pen systems and autoinjectors market was estimated to be worth over $0.58bn, a growth of 8-10% from previous years. It is estimated that the market will continue to grow steadily between 10-15% over the forecast period. It will reach $0.87bn in 2013 and $1.07bn in 2015. (Visiongain, June, 2011)
More info >>

Industry Events

Global Bioproduction Summit, 5th-6th February 2018

5-6 February 2018, Hilton San Diego Resort & Spa, CA

After 15 years in Europe, the Global Bioproduction Summit moved to its new home of San Diego in 2016. The Bioproduction Summit delves deep into the world of biological production.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement